SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320,
Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).